Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients
Purpose of the study is to compare the effects of megestrol acetate concentrated suspension and placebo on caloric intake for the treatment of cancer-associated anorexia in patients with lung or pancreatic cancer
Anorexia|Cachexia|Weight Loss
DRUG: Megestrol acetate concentrated suspension 110 mg/mL|DRUG: Placebo
Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase, The Nutrition Data System for Research (NDSR) was used to determine nutrient and caloric value for foods and beverages consumed and recorded by subjects over a 3-day assessment period prior to each visit. Total number of calories consumed during each 3-day assessment was averaged over available values to determine the week's daily caloric intake value., 8 weeks
Changes in Body Composition as Measured by Bioelectric Impedance Analysis (BIA) at Week 4 and Week 8 Relative to Baseline, Baseline, Week 4 and Week 8|Change in Weight Over the Course of the 8-week Double-blind Phase, Baseline, Week 1, 2, 3, 4, 6, and 8|Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale, Subjects marked 6 items on a visual analog scale (VAS) appetite scale including feeling not hungry to hungry, not nauseated to nauseated, empty to full, not satiated to satiated; weak to strong desire to eat; and ability to eat none to a large amount of food, Baseline, Weeks 1, 2, 3, 4, 6 and 8
Purpose of the study is to compare the effects of megestrol acetate concentrated suspension and placebo on caloric intake for the treatment of cancer-associated anorexia in patients with lung or pancreatic cancer